Genetic variant in visfatin gene promoter contributes to reduced risk of hepatocellular carcinoma in a Chinese population

Abstract

Knowledge on the role of gene variants in the visfatin promoter region in the hepatitis B virus (HBV)-related liver diseases is limited. In this study, we genotyped two potentially functional single nucleotide polymorphisms (SNPs) in the visfatin promoter region, -1535C>T (rs61330082) and -3187G>A (rs11977021), in 120 HBV-related chronic hepatitis B (CHB) patients, 140 HBV-related liver cirrhosis (HBV-LC) patients, 243 HBV-related hepatocellular carcinoma (HBV-HCC) patients, and 224 asymptomatic HBV carriers. Odds ratios (ORs) with 95% confidence intervals (CIs) were calculated by logistic regression. The results showed subjects with a TT genotype of -1535C>T had a significantly decreased risk of HBV-HCC related to the CC and CC + CT genotypes (adjusted OR = 0.493, 95% CI = 0.313-0.778; OR = 0.535, 95% CI = 0.362-0.791, respectively). A lowered risk also appeared in the comparison between allele T and allele C (OR = 0.734, 95%, CI = 0.581-0.950). However, these associations existed only in people with Zhuang ethnicity, but not in people with Han ethnicity. There were no significant associations between -3187G>A polymorphisms and the risk of HBV-related liver diseases. Our results suggested that visfatin -1535C>T polymorphisms might be associated with decreased risk of HBV-HCC among the ethnic Zhuang population in Guangxi, China.

Visfatin Polymorphisms, Lifestyle Risk Factors and Risk of Oral Squamous Cell Carcinoma in a Cohort of Taiwanese Males

“…Previous research has reported visfatin rs11977021 frequencies for CC, CT and TT genotypes among controls of 23.2%, 54.5% and 22.3%, respectively, and corresponding visfatin rs61330082 frequencies for CC, CT and TT genotypes among controls of 39.7%, 45.1% and 15.2%, respectively 17 . Another publication has reported visfatin rs2110385 frequencies for GG, GT and TT genotypes among controls of 75.6%, 24.4% and 0%, respectively (NCBI dbSNP HapMap-HCB population), and visfatin rs4730153 frequencies for GG, GA and AA genotypes among controls of 84.1%, 15.9% and 0%, respectively 28 .…”

“…Visfatin single-nucleotide polymorphisms (SNPs) rs11977021, rs61330082, rs2110385 and rs4730153 were chosen on the basis of prior research showing that they increased the risk of various cancers 14 , 17 - 19 . All SNPs had minor allele frequencies exceeding 5%.…”

Increased expression of insulin-like growth factor-1 receptor predicts poor prognosis in patients with hepatocellular carcinoma

“…The infections of HBV and HCV are major reasons for HCC onset, with the former one as the leading cause in China. [13] Five-year survival rate of patients with HCC is reportedly <10%. [14] Biomarkers are beneficial to early diagnosis, prognosis evaluation, and treatment in cancers.…”

Hepatokines and adipokines in NASH-related hepatocellular carcinoma

“…Increased visfatin is associated with a poor prognosis in patients with HCC [226,227], which is underlined by its association with HCC progression [228]. Significantly increased visfatin expressions were also seen in patients with liver cirrhosis compared to controls [227].…”